It has been reported that immunophenotypic CD34+CD19+ LICs may exist in human primary B-ALL bulk cells, which are responsible for the initiation, progression, relapse and drug resistance of B-ALL [4]. Here, CD19 is linked to acute lymphoblastic leukemia.